y. SAFETY INFORMATION FROM THE U. Febrile neutropenia has been prescribed to more than 00 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma. Across clinical trials (PALOMA-0, PALOMA-0, PALOMA-0), 0. Grade 0 or 0, and no fatal cases were reported. Advise women not to breastfeed during IBRANCE treatment and for 0 months after the last dose